Reading, United Kingdom (14 August 2017)
Convatec Group Plc (“Convatec” or “the Company”) is pleased to announce the appointments of Dr Regina Benjamin and Mrs Margaret Ewing as Non-Executive Directors of the Company, with immediate effect.
Dr Benjamin was United States Surgeon General from 2009 – 2013 and is currently a Non- Executive Director of Diplomat Pharmacy, Inc, Kaiser Foundation Hospitals and Health Plan, and Ascension Hospital System. She is a former Non-Executive Director of Alere, Inc. From 1992-2004 she served on the board of the Medical Association of Alabama, and in 1995, Dr Benjamin became the first Young Physician to be elected to the American Medical Association Board of Trustees. In 2008, she was Chair of the Federation of State Medical Licensing Boards. Dr Benjamin is CEO and practising physician at the Bayou La Batre Rural Health Clinic in Alabama, which she founded in 1990 and holds an endowed chair in Public Health Sciences at Xavier University of Louisiana. She will immediately join the Corporate Responsibility Committee.
Mrs Ewing is currently a Trustee of the Board and Chairman of the Finance and Audit Committee of Great Ormond Street Hospital Children’s Charity. She is also the Independent External member of the Audit Committee of the Lawn Tennis Association. Mrs Ewing was previously a Non-Executive Director of Standard Chartered plc, Whitbread plc and the Confederation of British Industry and the Independent External member of the Audit Committee of John Lewis Partnership plc. She was a corporate finance partner of Deloitte LLP between 1987 - 1999, returning to Deloitte in 2007 as a senior partner and retiring from the firm in 2012. During the period 2007 - 2012 Mrs Ewing was Vice Chairman and a member of the firm’s Executive Committee and the Board, Senior Partner of the London practice and latterly Managing Partner for Public Policy, Quality and Risk. Mrs Ewing was Group Chief Financial Officer of Trinity Mirror plc from 2000 - 2002 and of BAA plc from 2002 - 2006. She was also a Member of the Financial Reporting Review Panel between 2011 – 2014. She will immediately join the Audit and Risk Committee and Corporate Responsibility Committee.
It was previously announced that Dr Raj Shah would be leaving the Board of Convatec on 8th September 2017 following the reduction by Nordic Capital of their shareholding in the Company. Dr Ros Rivaz, who was appointed a Non-Executive Director of the Company on 21st June 2017, will immediately join the Nominations and Remuneration Committees in place of Dr Shah.
Sir Christopher Gent, Chairman of Convatec, commented:
“I am delighted to announce two appointments of individuals who bring a wealth of experience and knowledge to the Board. Also with the appointments of Regina and Margaret, we have fulfilled our promise to shareholders that we would appoint a Board which would comprise a majority of independent Directors and which would reflect the requirements and advantages of gender diversity. We look forward to benefitting from their contribution to the future success of the Company.”
This announcement is made in accordance with Listing Rule 9.6.11R(1).
In accordance with Listing Rule 9.6.13(1), Ms Ewing has confirmed that she was a director of Standard Chartered plc from 1st November 2012 to 31st January 2014, and Dr Benjamin has confirmed that she is currently a director of Diplomat Pharmacy, Inc and was a director of Alere, Inc from 12 December 2013 to 22 July 2015.
In accordance with Listing Rule 9.6.13(2) – (6), Ms Ewing and Dr Benjamin have advised that they have no details to disclose.
Bobby Leach, VP Group Corporate Affairs, Convatec +44 (0)7770 842 226
Alastair Elwen, Finsbury +44 (0)207 251 3801
Analysts and Investors
John Crosse, VP Investor Relations, Convatec +44 (0)7500 141 435
Kirsty Law, Director Investor Relations, Convatec +44 (0)7470 909 582
Convatec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion devices. Convatec’s products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about Convatec, please visit www.convatecgroup.com where a copy of this announcement can also be found.
Download this press releasePDF
Organisation AppointmentsRead more
FY2017 guidance and third quarter updateRead more
Convatec Introduces GentleCath™ Glide and me+™ Continence Care Programme for Intermittent Catheter Users in EuropeRead more
Scrip DividendRead more
Appointment to Executive CommitteeRead more
Convatec appoints two Non-Executive DirectorsRead more
Convatec Launches Natura™ Convex Accordion Flange™, Designed to Make Ostomy Pouch Application Easier and More ComfortableRead more
Convatec Announces 2017 Interim resultsRead more
03 August 2017 - Board ChangesRead more
Convatec Announces Acquisition of Woodbury HoldingsRead more
Announcement on Board of DirectorsRead more